Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novantrone/etoposide versus FLANG in relapsed or refractory acute leukemia
IRCT20190618043939N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jun 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of mitoxantrone, etoposide, fludarabine, cytarabine and granulocyte colony-stimulating factor, sponsored by Isfahan University of Medical Sciences. Started Jun 2019; status: completed.
02
Drugs
mitoxantroneetoposidefludarabinecytarabinegranulocyte colony-stimulating factor
Beyond the preview
Go deeper on IRCT20190618043939N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190618043939N1.